COVID boosters have a strong safety record backed by years of real-world data. Hundreds of millions of booster doses have been administered in the United States alone, and the vast majority of recipients experience nothing worse than a sore arm, headache, or mild fever that resolves within a day or two. Serious adverse events are rare, and the safety monitoring infrastructure surrounding these vaccines has been the most intensive in U.S. history.
What the Safety Data Shows
The clearest picture of booster safety comes from large-scale monitoring programs. In one CDC analysis covering over 700,000 adults who self-reported their experiences after a booster, side effects were actually less common after the booster than after the second dose of the initial series. For Moderna recipients, 64.4% reported systemic reactions (fever, fatigue, body aches) after the booster compared to 78.4% after dose two. For Pfizer recipients, 58.4% reported systemic reactions after the booster versus 66.7% after dose two.
Fewer than 1% of people in either group sought medical care afterward, and the difference between booster and second-dose medical visits was either not statistically significant or very small. The most commonly reported issues across all reporting systems were headache, fever, and injection-site pain, which is consistent with what you’d expect from any vaccine prompting an immune response.
Common Side Effects and How Long They Last
Most side effects show up within the first day or two and clear on their own. The typical experience includes soreness or swelling at the injection site, fatigue, headache, muscle aches, chills, and occasionally a low-grade fever. These reactions tend to be milder with the booster than they were with earlier doses in the primary series, likely because your immune system is responding more efficiently the second or third time around.
If you felt rough after your second shot, the booster is likely to be an easier experience. If your first series was smooth, the booster will probably be similar or milder still.
Myocarditis: The Rare Risk in Context
Myocarditis, an inflammation of the heart muscle, is the most talked-about serious side effect linked to mRNA COVID vaccines. It’s genuinely rare. Out of 81.2 million mRNA booster doses given to U.S. adults, 37 confirmed cases of myocarditis were reported to the national adverse event database. The highest rate was among men aged 18 to 24 after a Moderna booster, at roughly 8.7 cases per million doses.
When myocarditis does occur, it typically appears within seven days of vaccination, most often after the second dose rather than the booster. It’s far more common in adolescent and young adult males than in any other group. The prognosis is reassuring: surveys of patients diagnosed at least three months earlier found that 80% were considered fully or probably fully recovered by their cardiologist. Most people with post-vaccine pericarditis (inflammation of the tissue surrounding the heart) respond well to rest and standard medication and feel better quickly.
Safety During Pregnancy
Studies involving more than a million pregnant women worldwide have found no increased risk of miscarriage, preterm delivery, stillbirth, or birth defects from mRNA COVID vaccination before or during pregnancy. Side effects reported by pregnant women, such as headache, injection-site pain, and fever, matched what non-pregnant women experienced.
There’s also a direct benefit for the baby. Vaccination during pregnancy helps protect newborns younger than six months from COVID-related hospitalization, a period when infants are too young to be vaccinated themselves. Experts consider the vaccines unlikely to pose long-term health risks to babies based on how the mRNA platform works in the body.
Safety for Children and Adolescents
A large Canadian study tracked health events in children and adolescents after vaccination and compared them to unvaccinated peers. Among children under 5 and those aged 5 to 11, there were no significant differences in health events between vaccinated and unvaccinated groups after any dose. Among adolescents, a modest increase in health events (defined as anything preventing daily activities or requiring a medical visit) appeared after the second dose: 4.6% for Pfizer recipients versus 3.7% in unvaccinated controls.
Myocarditis in this age group followed the same pattern seen in adults, concentrated in male adolescents after dose two. The rate was 0.037% among those who received two Pfizer doses and higher at 0.529% among those who received two Moderna doses, reinforcing why Pfizer has generally been the preferred option for younger age groups.
People With Autoimmune Conditions
If you have an autoimmune disease like rheumatoid arthritis, lupus, Hashimoto’s thyroiditis, or inflammatory bowel disease, you may wonder whether a booster could trigger a flare. A large study analyzing tens of thousands of patients across more than a dozen autoimmune conditions found that adverse events tended to cluster in the first week after vaccination, with another, smaller bump appearing after the sixth week. This pattern held across conditions.
The study found a consistent female predominance in reported adverse events, which tracks with the fact that autoimmune diseases themselves are more common in women. Serious outcomes like hospitalization were predictable based on factors like age, sex, and dose number, suggesting that most people with autoimmune conditions can anticipate their risk with reasonable accuracy by discussing their specific situation with their care team.
How Safety Monitoring Works
COVID vaccines have been tracked through multiple overlapping systems. The national adverse event reporting system collects reports from anyone, healthcare providers and patients alike, and flags potential safety signals. A separate app-based system allowed millions of vaccinated people to log their symptoms daily in the week following each dose, creating a real-time picture of common reactions. Additional monitoring through large health insurance databases and hospital networks provided yet another layer of oversight.
Several of these systems were built specifically for the pandemic and added capabilities that didn’t exist for previous vaccines. The result is that COVID boosters have more post-market safety data behind them than any vaccine in history. As of mid-2025, the FDA has advised manufacturers to update the fall 2025-2026 formula to target the JN.1 lineage of the virus, preferentially using the LP.8.1 strain, and continues to monitor both safety and effectiveness on an ongoing basis.
Serious Events Are Rare Overall
Of nearly 40,000 adverse event reports submitted to the national reporting system after mRNA boosters in adults, 92.4% were classified as non-serious. The remaining 7.6% classified as serious included any event resulting in hospitalization, disability, or death, but “reported” does not mean “caused by.” The reporting system captures events that happen after vaccination regardless of whether the vaccine was responsible, and each serious report is investigated individually.
The overall pattern across millions of doses, multiple monitoring systems, and years of follow-up is consistent: COVID boosters carry a small risk of short-lived side effects for most people, a very small risk of myocarditis concentrated in young men, and an extremely small risk of other serious events. For the vast majority of people, the safety profile is comparable to other routine vaccines.